GSK 3640254

Drug Profile

GSK 3640254

Alternative Names: BMS 986197; GSK-3640254

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer ViiV Healthcare
  • Class Antiretrovirals
  • Mechanism of Action Capsid protein inhibitors; HIV integrase inhibitors; HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 19 Jun 2018 ViiV Healthcare initiates a phase I pharmacokinetic trial in HIV infections (In volunteers) in UK (PO) (NCT03575962)
  • 19 Sep 2017 Phase-I clinical trials in HIV infections (In volunteers) in United Kingdom (PO) (NCT03231943)
  • 19 Sep 2017 Preclinical trials in HIV infections in United Kingdom (PO) before September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top